Select Topic:
Browse by Series:

I-O Therapy in mCRC: Ipilimumab + Nivolumab

Insights From: Tanios Bekaii-Saab, MD, Mayo Clinic; Johanna C. Bendell, MD, Sarah Cannon Research Institute
Published: Tuesday, Nov 13, 2018



Transcript:

Johanna C. Bendell, MD: For patients with microsatellite instable [MSI] colorectal cancer, we have seen benefits of immunotherapy. We do have multiple FDA approvals for these patients of agents, including pembrolizumab, nivolumab, and now nivolumab plus ipilimumab. We see single-agent response rates in the range of 30% to 50% for patients with PD-1 inhibitors, and we also know that patients who respond to these PD-1 inhibitors tend to have very prolonged responses.

The CheckMate-142 study looked both at single-agent nivolumab and nivolumab plus ipilimumab. The 2 arms weren
Slider Left
Slider Right


Transcript:

Johanna C. Bendell, MD: For patients with microsatellite instable [MSI] colorectal cancer, we have seen benefits of immunotherapy. We do have multiple FDA approvals for these patients of agents, including pembrolizumab, nivolumab, and now nivolumab plus ipilimumab. We see single-agent response rates in the range of 30% to 50% for patients with PD-1 inhibitors, and we also know that patients who respond to these PD-1 inhibitors tend to have very prolonged responses.

The CheckMate-142 study looked both at single-agent nivolumab and nivolumab plus ipilimumab. The 2 arms weren
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x